Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone781-547-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees45
OptionableNot Optionable
Histogenics (NASDAQ:HSGX) Frequently Asked Questions
What is Histogenics' stock symbol?
Histogenics trades on the NASDAQ under the ticker symbol "HSGX."
How were Histogenics' earnings last quarter?
Histogenics Corp (NASDAQ:HSGX) released its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.05. View Histogenics' Earnings History.
When is Histogenics' next earnings date?
What price target have analysts set for HSGX?
4 brokers have issued 1-year target prices for Histogenics' stock. Their predictions range from $1.00 to $5.00. On average, they anticipate Histogenics' share price to reach $3.1667 in the next year. This suggests a possible upside of 1,945.7% from the stock's current price. View Analyst Price Targets for Histogenics.
What is the consensus analysts' recommendation for Histogenics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Histogenics.
What are Wall Street analysts saying about Histogenics stock?
Here are some recent quotes from research analysts about Histogenics stock:
- 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (1/15/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $21/share is based on an equally-weighted composite of: (a) $12.6/share, as a 35x multiple of taxed and diluted $3.85 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $29.3/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Translate Bio, Inc." (12/24/2018)
Has Histogenics been receiving favorable news coverage?
Media coverage about HSGX stock has trended very positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Histogenics earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are some of Histogenics' key competitors?
Who are Histogenics' key executives?
Histogenics' management team includes the folowing people:
- Adam D. Gridley, President, Chief Executive Officer & Director
- Stephen R. Kennedy, Chief Operating Officer & Executive Vice President
- Jonathan I. Lieber, Chief Financial Officer & Treasurer
- E. Lynne Kelley, Chief Medical Officer
- Peter Hamilton, Vice President-Operations & Engineering
When did Histogenics IPO?
(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Histogenics?
Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Histogenics' stock price today?
One share of HSGX stock can currently be purchased for approximately $0.1548.
How big of a company is Histogenics?
Histogenics has a market capitalization of $9.60 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.
What is Histogenics' official website?
How can I contact Histogenics?
Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]
MarketBeat Community Rating for Histogenics (NASDAQ HSGX)
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
